Search

Your search keyword '"Radic, Haja Dominike"' showing total 6 results
Start Over Author "Radic, Haja Dominike"
6 results on '"Radic, Haja Dominike"'

1. Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens

Author

Draghi, Arianna, primary, Chamberlain, Christopher Aled, additional, Khan, Shawez, additional, Papp, Krisztian, additional, Lauss, Martin, additional, Soraggi, Samuele, additional, Radic, Haja Dominike, additional, Presti, Mario, additional, Harbst, Katja, additional, Gokuldass, Aishwarya, additional, Kverneland, Anders, additional, Nielsen, Morten, additional, Westergaard, Marie Christine Wulff, additional, Andersen, Mads Hald, additional, Csabai, Istvan, additional, Jönsson, Göran, additional, Szallasi, Zoltan, additional, Svane, Inge Marie, additional, and Donia, Marco, additional

Published
2021
Full Text
View/download PDF

2. This title is unavailable for guests, please login to see more information.

Author

Draghi, Arianna, Chamberlain, Christopher Aled, Khan, Shawez, Papp, Krisztian, Lauss, Martin, Soraggi, Samuele, Radic, Haja Dominike, Presti, Mario, Harbst, Katja, Gokuldass, Aishwarya, Kverneland, Anders, Nielsen, Morten, Westergaard, Marie Christine Wulff, Andersen, Mads Hald, Csabai, Istvan, Jönsson, Göran, Szallasi, Zoltan, Svane, Inge Marie, Donia, Marco, Draghi, Arianna, Chamberlain, Christopher Aled, Khan, Shawez, Papp, Krisztian, Lauss, Martin, Soraggi, Samuele, Radic, Haja Dominike, Presti, Mario, Harbst, Katja, Gokuldass, Aishwarya, Kverneland, Anders, Nielsen, Morten, Westergaard, Marie Christine Wulff, Andersen, Mads Hald, Csabai, Istvan, Jönsson, Göran, Szallasi, Zoltan, Svane, Inge Marie, and Donia, Marco

Published
2021

3. This title is unavailable for guests, please login to see more information.

Author

Draghi, Arianna, Chamberlain, Christopher Aled, Khan, Shawez, Papp, Krisztian, Lauss, Martin, Soraggi, Samuele, Radic, Haja Dominike, Presti, Mario, Harbst, Katja, Gokuldass, Aishwarya, Kverneland, Anders, Nielsen, Morten, Westergaard, Marie Christine Wulff, Andersen, Mads Hald, Csabai, Istvan, Jönsson, Göran, Szallasi, Zoltan, Svane, Inge Marie, Donia, Marco, Draghi, Arianna, Chamberlain, Christopher Aled, Khan, Shawez, Papp, Krisztian, Lauss, Martin, Soraggi, Samuele, Radic, Haja Dominike, Presti, Mario, Harbst, Katja, Gokuldass, Aishwarya, Kverneland, Anders, Nielsen, Morten, Westergaard, Marie Christine Wulff, Andersen, Mads Hald, Csabai, Istvan, Jönsson, Göran, Szallasi, Zoltan, Svane, Inge Marie, and Donia, Marco

Published
2021

4. Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses:implications for the management of irAEs

Author

Draghi, Arianna, Borch, Troels Holz, Radic, Haja Dominike, Chamberlain, Christopher Aled, Gokuldass, Aishwarya, Svane, Inge Marie, Donia, Marco, Draghi, Arianna, Borch, Troels Holz, Radic, Haja Dominike, Chamberlain, Christopher Aled, Gokuldass, Aishwarya, Svane, Inge Marie, and Donia, Marco

Abstract

Up to 60% of patients treated with cancer immunotherapy develop severe or life threatening immune-related adverse events (irAEs). Immunosuppression with high dose corticosteroids, or tumor necrosis factor (TNF) antagonists in refractory cases, is the mainstay of treatment for irAEs. It is currently unknown what impact corticosteroids and anti-TNF have on the activity of antitumor T cells. In our study, the influence of clinically relevant doses of dexamethasone (corresponding to an oral dose of 10–125 mg prednisolone) and infliximab (anti-TNF) on the activation and killing ability of tumor-infiltrating lymphocytes (TILs) was tested in vitro. Overall, dexamethasone at low or intermediate/high doses impaired the activation (−46 and −62%, respectively) and tumor-killing ability (−48 and −53%, respectively) of tumor-specific TILs. In contrast, a standard clinical dose of infliximab only had a minor effect on T cell activation (−20%) and tumor killing (−10%). A 72-hr resting period after withdrawal of dexamethasone was sufficient to rescue the in vitro activity of TILs, while a short withdrawal did not result in a full rescue. In conclusion, clinically relevant doses of infliximab only had a minor influence on the activity of tumor-specific TILs in vitro, whereas even low doses of corticosteroids markedly impaired the antitumor activity of TILs. However, the activity of TILs could be restored after withdrawal of steroids. These data indirectly support steroid-sparing strategies and early initiation of anti-TNF therapy for the treatment of irAEs in immuno-oncology.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results